Ceryvyn Therapeutics Limited
CYVNY
$0.02
-$0.01-35.00%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -100.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -100.00% | |||
| SG&A Expenses | 0.39% | -31.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 0.35% | -- | |||
| Total Operating Expenses | 0.39% | -27.69% | |||
| Operating Income | -0.39% | 27.68% | |||
| Income Before Tax | -0.39% | -102.99% | |||
| Income Tax Expenses | -0.33% | -574.23% | |||
| Earnings from Continuing Operations | -0.39% | -102.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.39% | -102.91% | |||
| EBIT | -0.39% | 27.68% | |||
| EBITDA | -0.39% | 27.70% | |||
| EPS Basic | 0.00% | -102.87% | |||
| Normalized Basic EPS | 0.00% | -102.86% | |||
| EPS Diluted | 0.00% | -102.87% | |||
| Normalized Diluted EPS | 0.00% | -102.86% | |||
| Average Basic Shares Outstanding | 0.00% | 2.71% | |||
| Average Diluted Shares Outstanding | 0.00% | 2.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||